北京市中伦律师事务所 关于国科恒泰（北京）医疗科技股份有限公司 2024 年年度股东大会的 法律意见书 二〇二五年五月 北京市中伦律师事务所 关于国科恒泰（北京）医疗科技股份有限公司 務 所 法律意见书 目 录 | | 本次股东大会的召集、召开程序 . | | --- | --- | | i í | 出席本次股东大会人员和会议召集人资格 | | 111 | 本次股东大会的表决程序和表决结果 | | 四、 | 结论意见… | 2 2024 年年度股东大会的 法律意见书 致：国科恒泰（北京）医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）受国科恒泰（北京）医疗科技 股份有限公司（以下简称"公司"）委托，指派律师见证公司 2024 年年度股东大 会（以下简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》（以 下简称"《公司法》"）等相关法律、法规、规范性文件及《国科恒泰（北京）医 疗科技股份有限公司章程》（以下简称"《公司章程》"）的规定，对本次股东大会 进行见证并出具法律意见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业 ...

证券代码：301370 证券简称：国科恒泰 公告编号：2025-028 国科恒泰（北京）医疗科技股份有限公司 2024 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 2、会议召开地点：北京市北京经济技术开发区经海四路 25 号 6 号楼公司 410 会议室。 3、会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 4、会议召集人：公司第三届董事会。 5、会议主持人：董事长刘冰先生主持。 1、本次股东大会不存在否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议的召开和出席情况 （一）会议的召开情况 1、会议的召开时间： 现场会议时间：2025 年 5 月 16 日（星期五）下午 15:00 网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为：2025 年 5 月 16 日上午 9:15-9:25，9:30-11:30 和下午 13:00-15:00；通过深圳证券交易所互 联网系统投票的具体时间为：2025 年 5 月 16 日上午 9:15 至下午 15:00 的任意时 间 ...

Group 1 - The DRG/DIP concept declined by 3.30%, ranking among the top declines in the concept sector, with notable declines in companies such as Chuangying Huikang, ST Yilianzhong, and Jiahe Meikang [1][2] - The DRG/DIP concept experienced a net outflow of 4.92 billion yuan in main funds, with 19 stocks seeing net outflows, and 13 stocks with outflows exceeding 10 million yuan [2] - The stock with the highest net outflow was Donghua Software, with a net outflow of 1.26 billion yuan, followed by Chuangying Huikang, Weining Health, and Dian Diagnosis [2][3] Group 2 - The top stocks with net outflows in the DRG/DIP concept included Donghua Software (-3.97%), Chuangying Huikang (-6.76%), and Weining Health (-4.60%) [2][3] - Conversely, the stocks with net inflows included Huaping Co., Guoke Hengtai, and Wanda Information, with net inflows of 238.84 million yuan, 166.15 million yuan, and 121.00 million yuan respectively [2]

Group 1: Business Competitiveness and Strategy - The company's core competitive advantages include warehousing logistics, information systems, professional teams, and integrated management capabilities, which create barriers in upstream production, inventory scale, and terminal medical institution resources [1] - Currently, there are no acquisition plans, but the company acknowledges that mergers and acquisitions play a significant role in strengthening and expanding operations [2] Group 2: Growth Drivers and Market Trends - The demand for vascular intervention products is driven by the aging population, with a significant positive correlation between the prevalence of cardiovascular diseases and age [2] - The company aims to expand its product offerings beyond vascular intervention and orthopedics, focusing on equipment and IVD categories [2] Group 3: Performance Goals and Risk Management - The management is committed to daily operations and exploring new development paths to uncover new profit growth points, aiming for better performance to reward investors [2] - The company plans to adopt a diversified supply chain strategy to mitigate trade risks and reduce reliance on single sources or brands, while maintaining partnerships with large multinational companies [2]

证券代码：301370 证券简称：国科恒泰 公告编号：2025-027 国科恒泰（北京）医疗科技股份有限公司 关于举行 2024 年度暨 2025 年第一季度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 国科恒泰（北京）医疗科技股份有限公司（以下简称"公司"）已于 2025 年 4 月 25 日在巨潮资讯网披露《2024 年年度报告》《2024 年年度报告摘要》及《2025 年第一季度报告》。为便于广大投资者更加全面深入地了解公司经营业绩、发展战 略等情况，公司定于 2025 年 5 月 19 日（星期一）15:00-17:00 举办公司 2024 年度 暨 2025 年第一季度业绩说明会，与投资者进行沟通和交流，广泛听取投资者的意 见和建议。现将有关安排公告如下： 现场会议召开地点：证券日报元宇宙路演中心（北京市西城区车公庄大街 21 号院 39 幢首创新大都 1 号楼 3 层） 网络会议参与方式：投资者可登录证券日报网路演平台（http://www.zqrb.cn/h uiyi/lyhd/index.html）参与本次业绩说明会。 二、 ...

长城证券股份有限公司 关于国科恒泰（北京）医疗科技股份有限公司 2024 年度持续督导现场培训情况报告 长城证券股份有限公司（以下简称"长城证券"或"保荐机构"）作为国科 恒泰（北京）医疗科技股份有限公司（以下简称"国科恒泰"或"公司"）首次 公开发行股票并在创业板上市的保荐机构和持续督导机构，根据《证券发行上市 保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所 上市公司自律监管指引第 13 号——保荐业务》等相关规定，对国科恒泰进行了 2024 年度持续督导现场培训，相关情况如下： 一、培训对象 国科恒泰董事、监事、高级管理人员、中层以上管理人员及公司控股股东和 实际控制人代表等相关人员。 五、培训成果 通过本次培训，使国科恒泰控股股东及实际控制人、董事、监事、高级管理 人员等相关方进一步知晓上市公司治理、募集资金管理和使用、信息披露、大股 东和董监高股份减持等方面的法律法规；知悉上市公司规范运作方面的责任和义 务；进一步明确了作为公司董事、监事、高级管理人员及控股股东和实际控制人 的责任与义务；提高了培训对象 ...

长城证券股份有限公司 关于国科恒泰（北京）医疗科技股份有限公司 2024 年度持续督导定期现场检查报告 （3）查阅公司内部控制评价报告，向公司内审部门人员了解公司内部控制的有效性； | 保荐人名称：长城证券股份有限公司 | 被保荐公司简称：国科恒泰 | | | | --- | --- | --- | --- | | 保荐代表人姓名：张涛 | 联系电话：0755-83516222 | | | | 保荐代表人姓名：李宛真 | 联系电话：0755-83516222 | | | | 现场检查人员姓名：张涛、刘斌、常晋意 | | | | | 现场检查对应期间：2024 年 1 月 1 日至 2024 年 12 月 31 日 | | | | | 现场检查时间：2025 年 月 日、23 日-24 日 4 21 | | | | | 一、现场检查事项 | 现场检查意见 | | | | （一）公司治理 | 是 | 否 | 不适用 | | 现场检查手段： | | | | | （1）查阅公司章程和公司治理相关制度，并访谈董事会秘书了解其执行情况； | | | | | （2）查阅公司股东会、董事会文件及相关信息披露文件； | | | ...

Group 1 - Shengxiang Bio plans to increase its investment in Hunan Shengwei Kunteng Biotechnology Co., Ltd. by 100 million yuan to enhance its industrial chain layout in the POCT field, resulting in a 44.6441% stake in Shengwei Kunteng after the investment [1] - Yaguang Technology's subsidiary Chengdu Yaguang signed a product pre-production agreement worth 101 million yuan, accounting for 10.56% of the company's audited revenue for the last fiscal year [1] Group 2 - Chutianlong's shareholder plans to reduce its stake by up to 3%, equating to 13.83 million shares, due to personal funding needs [2] - Naipu Mining intends to invest up to 45 million USD in Swiss Veritas Resources AG, acquiring a 22.5% stake to extend its industrial chain [2][3] Group 3 - Diri Medical's shareholder plans to reduce its stake by up to 3%, totaling 814.83 thousand shares, due to funding needs [4] - Kangtai Medical's controlling shareholder plans to reduce its stake by up to 2.99%, equating to 12 million shares [5] Group 4 - Iwu Bio's controlling shareholder plans to transfer up to 450 thousand shares through block trading, representing 0.86% of the total share capital [7] - Guokai Hengtai's four shareholders plan to collectively reduce their stake by up to 4.7%, totaling 22.94 million shares [9] Group 5 - *ST Zhongcheng submitted a hearing application to the Shenzhen Stock Exchange in response to a delisting notice [10] - Donghua Software's actual controller and associated parties plan to reduce their stake by up to 1%, totaling 32.05 million shares [12] Group 6 - Shandong Molong's shareholder reduced its H-share holdings by 107 million shares, representing 13.39% of the total share capital [12] - Yinbang Co.'s shareholder plans to reduce its stake by up to 1%, totaling 821.92 thousand shares [13] Group 7 - Jinxinnong reported April sales of 10.65 million pigs, generating sales revenue of 139 million yuan, with an average selling price of 15.05 yuan per kilogram [14] - Dongfang Jiasheng purchased 9.54 million shares of Zhonggu Logistics for approximately 99.72 million yuan, representing 4.18% of the company's net assets [15] Group 8 - Linglong Tire's controlling shareholder received a financing commitment of up to 270 million yuan for stock repurchase [16] - Wuchan Jinlun's shareholder plans to reduce its stake by up to 3%, totaling 619.77 thousand shares [18] Group 9 - Pengyao Environmental's directors and executives plan to collectively reduce their stake by up to 0.07% [19] - Ruihu Mould's controlling shareholder plans to reduce its stake by up to 1.92%, totaling 401.89 thousand shares [20] Group 10 - Electric Alloy's shareholder plans to reduce its stake by up to 0.63%, totaling 210.88 thousand shares [22] - Shanghai Xinyang's controlling shareholder plans to reduce its stake by up to 0.64%, totaling 200 thousand shares [24] Group 11 - Sujiao Ke's controlling shareholder plans to acquire up to 2% of the company's shares from a fund [26] - Heyuan Bio's shareholders plan to reduce their stake by up to 1%, totaling 649.04 thousand shares [27]

Group 1 - The issuance scale of equity funds in China has exceeded 50% of the total new fund issuance in 2025, with a total of 340 billion yuan, marking a significant increase compared to previous years [1] - The People's Bank of China and the China Securities Regulatory Commission have announced support for the issuance of technology innovation bonds, leading to a surge in issuance plans from various financial institutions and enterprises, with a total issuance scale exceeding 210 billion yuan [1] - The recent drop in housing provident fund loan rates in major cities like Beijing, Shanghai, Guangzhou, and Shenzhen aims to stimulate the housing market, with the new rates at historical lows of 2.6% for first-time buyers [2] Group 2 - The humanoid robot sector has gained renewed attention in the A-share market, with significant investment interest from private equity firms, as the industry is expected to transition from the concept phase to mass production by 2025 [3] - The domestic computing power industry is experiencing a surge in interest, with stocks related to computing power, cloud computing, and AI showing over 10% growth from February to April, driven by strong demand and favorable policies [4] - In the past month, 370 A-share companies have announced share repurchase and increase plans, with a total repurchase amount reaching approximately 681.94 billion yuan [4] Group 3 - SAIC's mobility brand, Xiangdao, has completed over 1.3 billion yuan in Series C financing, marking the largest single financing in the domestic mobility sector in three years, and plans to establish a Robotaxi fleet by 2026 [5] - Xidi Technology has submitted a listing application to the Hong Kong Stock Exchange, indicating a growing trend of tech companies seeking public listings [6] - CITIC Bank plans to establish a wholly-owned subsidiary with a capital of 10 billion yuan to enhance support for technology innovation enterprises and the private economy [10]

国科恒泰：四位股东拟合计减持不超4.7%公司股份 金十数据5月8日讯，国科恒泰公告称，股东国丰鼎嘉、国科鼎奕、国科瑞鼎、国科嘉和金源拟合计减持 不超过4.7%的公司股份。 ...